ONE-WAYDated event · through FY2027-H1
In-licensing of Exclusive Development and Commercialization Rights in Japan for MHB018A
A project to in-license exclusive development and commercialization rights in Japan for MHB018A, a treatment for thyroid eye disease, from Minghui Pharmaceutical and advance its development and commercialization in exchange for an upfront payment, development and sales milestones, and royalties.
Companies1How many companies write about this.
Threads1One company can carry more than one thread here.
PeriodFY2027-H1 →Last written FY2027-H1
Directionhelps1 helps · 0 hurts · 0 flat